Abstract | PURPOSE: METHODS: Total midgut I/R injury in rats was achieved by occlusion of a first-order branch of the superior mesenteric artery for 60 minutes, followed by reperfusion for 6 hours. Rats were treated with HB-EGF 5 minutes before ischemia, halfway through the ischemic event, or 5 minutes after ischemia. Route of administration was tested by administering HB-EGF either intraluminally or intravenously. Seven different doses of HB-EGF were tested. RESULTS: CONCLUSION: These data demonstrate that HB-EGF acts as an effective intestinal cytoprotective agent when administered intraluminally not only before injury, but also during injury and, most importantly, even after intestinal injury has already occurred. These findings support a basis for the prophylactic use of intraluminal HB-EGF in high-risk patients, as well as for the administration of HB-EGF to salvage patients in whom an intestinal insult has already occurred.
|
Authors | Abigail E Martin, Mark H Luquette, Gail E Besner |
Journal | Journal of pediatric surgery
(J Pediatr Surg)
Vol. 40
Issue 11
Pg. 1741-7
(Nov 2005)
ISSN: 1531-5037 [Electronic] United States |
PMID | 16291163
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- HBEGF protein, human
- Hbegf protein, rat
- Heparin-binding EGF-like Growth Factor
- Intercellular Signaling Peptides and Proteins
- Epidermal Growth Factor
|
Topics |
- Animals
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Epidermal Growth Factor
(administration & dosage, pharmacology)
- Heparin-binding EGF-like Growth Factor
- Humans
- Infusions, Intravenous
- Intercellular Signaling Peptides and Proteins
- Intestines
(blood supply)
- Ischemia
- Rats
- Rats, Sprague-Dawley
- Reperfusion Injury
(prevention & control)
- Risk Factors
- Salvage Therapy
|